Jun 20, 2024, 11:37
Filippo Montemurro: Intriguing preclinical findings of synergy between fulvestrant and capecitabile in ESR1 tumors
Filippo Montemurro, Senior Medical Director at Roche, shared on X:
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. Very intriguing preclinical findings of synergy between fulvestrant and capecitabile in ESR1 mutant tumors.
Read further
Source: Filippo Montemurro/X